- Home
- NBTX vs ELDN Comparison
NBTX vs ELDN Comparison
Compare NBTX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- ELDN
- Stock Information
- Founded
- NBTX 2003
- ELDN 2004
- Country
- NBTX France
- ELDN United States
- Employees
- NBTX N/A
- ELDN N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- ELDN Health Care
- Exchange
- NBTX Nasdaq
- ELDN Nasdaq
- Market Cap
- NBTX 211.9M
- ELDN 178.4M
- IPO Year
- NBTX 2020
- ELDN N/A
- Fundamental
- Price
- NBTX $4.57
- ELDN $2.79
- Analyst Decision
- NBTX Strong Buy
- ELDN Strong Buy
- Analyst Count
- NBTX 1
- ELDN 2
- Target Price
- NBTX $8.00
- ELDN $12.50
- AVG Volume (30 Days)
- NBTX 7.1K
- ELDN 618.2K
- Earning Date
- NBTX 04-02-2025
- ELDN 08-18-2025
- Dividend Yield
- NBTX N/A
- ELDN N/A
- EPS Growth
- NBTX N/A
- ELDN N/A
- EPS
- NBTX N/A
- ELDN N/A
- Revenue
- NBTX N/A
- ELDN N/A
- Revenue This Year
- NBTX N/A
- ELDN N/A
- Revenue Next Year
- NBTX $221.06
- ELDN N/A
- P/E Ratio
- NBTX N/A
- ELDN N/A
- Revenue Growth
- NBTX N/A
- ELDN N/A
- 52 Week Low
- NBTX $2.76
- ELDN $2.30
- 52 Week High
- NBTX $6.00
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- NBTX 52.43
- ELDN 45.10
- Support Level
- NBTX $4.31
- ELDN $2.60
- Resistance Level
- NBTX $5.00
- ELDN $2.91
- Average True Range (ATR)
- NBTX 0.26
- ELDN 0.17
- MACD
- NBTX -0.06
- ELDN -0.00
- Stochastic Oscillator
- NBTX 24.44
- ELDN 36.54
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.